Patents by Inventor Peter David Davis
Peter David Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240071593Abstract: Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.Type: ApplicationFiled: October 24, 2023Publication date: February 29, 2024Inventors: Anna Leigh DAVIS, Scott M. BELLIVEAU, Naresh C. BHAVARAJU, Leif N. BOWMAN, Rita M. CASTILLO, Alexandra Elena CONSTANTIN, Rian W. DRAEGER, Laura J. DUNN, Gary Brian GABLE, Arturo GARCIA, Thomas HALL, Hari HAMPAPURAM, Christopher Robert HANNEMANN, Anna Claire HARLEY-TROCHIMCZYK, Nathaniel David HEINTZMAN, Andrea Jean JACKSON, Lauren Hruby JEPSON, Apurv Ullas KAMATH, Katherine Yerre KOEHLER, Aditya Sagar MANDAPAKA, Samuel Jere MARSH, Gary A. MORRIS, Subrai Girish PAI, Andrew Attila PAL, Nicholas POLYTARIDIS, Philip Thomas PUPA, Eli REIHMAN, Ashley Anne RINDFLEISCH, Sofie Wells SCHUNK, Peter C. SIMPSON, Daniel S. SMITH, Stephen J. VANSLYKE, Matthew T. VOGEL, Tomas C. WALKER, Benjamin Elrod WEST, Atiim Joseph WILEY
-
Publication number: 20150141349Abstract: This invention relates to methods and compositions for treating carcinoid syndrome and other adverse symptoms associated with tumor-producing neuroendocrine tumors, said methods comprising administering a therapeutically effective amount of a vascular disrupting agent, or a pharmaceutically acceptable salt thereof, to a subject having a hormone producing neuroendocrine tumor. In preferred implementations, the vascular disrupting agent is combretastatin A-4 phosphate, combretastatin A-1 diphosphate, or a pharmaceutical acceptable salt thereof.Type: ApplicationFiled: June 21, 2013Publication date: May 21, 2015Applicant: Angiogene Pharmaceuticals Ltd.Inventors: Peter David Davis, David J. Chaplin
-
Publication number: 20090202571Abstract: A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; -R2 is a glycoside, OH, optionally substituted alkyl, optionally substituted alkoxy, C2-C8 alkenyl, C1-C8 hydroxyalkyl, optionally substituted arylamino, optionally substituted aryl C1-C4 alkylamino or hydroxyalkylamino; and -R3 and R4 are each independently H or halo.Type: ApplicationFiled: September 26, 2005Publication date: August 13, 2009Applicants: HOPNIC LABORATORY CO., LTD., DAISO CO.,LTD.Inventors: Peter David Davis, Matthew Alexander Naylor, Peter Thomson, Steven Albert Everett, Michael Richard Lacey Stratford, Peter Wardman
-
Publication number: 20080145372Abstract: The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally substituted benzoquinone, optionally substituted naphthoquinone or optionally substituted fused heterocycloquinone: R2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, aryl or heteroaryl; and R3 is selected such that R3NH2 represents a cytotoxic nucleoside analogue or an ester or phosphate ester prodrug of a cytotoxic nucleoside analogue, with the proviso that if R1 is an aryl group then R2 is not H.Type: ApplicationFiled: September 26, 2005Publication date: June 19, 2008Applicants: ANGIOGENE, PHARMACEUTICALS LIMITED, THE GRAY LABORATORY CANCER RESEARCH TRUSTInventors: Peter David Davis, Matthew Alexander Naylor, Peter Thomson, Steven Albert Everett, Michael Richard Lacey Stratford, Peter Wardman
-
Patent number: 7265136Abstract: A compound for use in inducing necrosis in vascular tissue of a tumor in an animal. The compound contains a first moiety which is a cis-stilbene moiety and a second moiety which is an inhibitor of the formation or action of nitric acid. Also, a method for inducing necrosis in vasculature of a tumor in an animal by administering to the animal the compound in an amount effective for inducing the necrosis.Type: GrantFiled: February 15, 2000Date of Patent: September 4, 2007Assignee: Angiogene Pharmaceuticals Ltd.Inventor: Peter David Davis
-
Patent number: 7105501Abstract: Compositions for the inhibition of the formation of new vaculature by angiogenesis are provided as in compounds which are salts comprising as an acidic component a compound of formula (1) wherein: R1, R2 and R3 are each independently alkyl, R4 is alkoxy, haloalkoxy, alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl, hydroxy or halo, R5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxy, phosphate or halo, and, as the basic component, a compound selected from the group consisting of (2) a compound of formula (2) wherein R6 is hydrogen or alkyl R7 is alkyl, alkylamino, dialkylamino, nitroamino, hydrazine, mercapto or alkylthio X is CH2, CH2CH2, CH2S, CH2CH2S Y is NH or S or a compound of formula (3) wherein R8 is alkyl or aminoalkyl R9 is hydrogen, alkyl or optionally substituted phenyl or, a compound of formula (4) wherein Z is O, S, CH2, CHR13 or a bond R10, R11, R12 and R13 are each independently alkyl or hydrogen or, a compound of formula (5) wherein R14 is alkyl and the pharmaceuticType: GrantFiled: February 14, 2003Date of Patent: September 12, 2006Assignee: Angiogene Pharmaceuticals Ltd.Inventor: Peter David Davis
-
Patent number: 7087627Abstract: Compositions for the inhibition of the formation of new vasculature by angiogenesis are provided comprising the combination of a vasculature damaging agent and an inhibitor of the formation or action of nitric oxide in mammalian systems. There are also provided the use of said combinations in medicaments and kits of said compounds and treatment employing said materials.Type: GrantFiled: February 15, 2000Date of Patent: August 8, 2006Assignee: Angiogene Pharmaceuticals Ltd.Inventor: Peter David Davis
-
Patent number: 7081469Abstract: Vascular damaging agents composed of substituted 5(6)-substituted benzimidazole-2-carbamates are provided. These agents are useful in the preparation of medicaments for the treatment of diseases involving neovascularisation, particularly for the treatment of solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis. Embodiments include a 5(6)-substituted benzimidazole-2-carbamate of formula I wherein A represents a multi-substituted alkyl group or aromatic ring.Type: GrantFiled: July 3, 2003Date of Patent: July 25, 2006Assignee: Angiogene Pharmaceuticals Ltd.Inventor: Peter David Davis
-
Patent number: 7012076Abstract: Fused bicyclic amines of formula (1) are described wherein Ar is an aryl or heteroaryl group; Y is a —S(O2)— or —C(O)— group; R1 is a hydrogen or halogen atom or an alkyl, haloalkyl, alkoxy, haloalkoxy or cyano group; X is a nitrogen atom or a C(R1a) group where R1a is as defined for R1 and may be the same or different; W and Z are each a carbon atom and together with U form an optionally substituted five- or six-membered monocyclic aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the activity of Class 1 receptor tyrosine kinases and are of use in the prophylaxis and treatment of hyperproliferative disorders such as cancer, psoriasis, restenosis, atherosclerosis and fibrosis.Type: GrantFiled: March 29, 2001Date of Patent: March 14, 2006Assignee: Celltech R&D LimitedInventors: David Festus Charles Moffat, Peter David Davis
-
Patent number: 6906048Abstract: The invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of the following therapies: i) ionizing radiation; ii) a platinum anti-tumor agent; and iii) a taxane.Type: GrantFiled: March 27, 2001Date of Patent: June 14, 2005Assignee: AstraZeneca ABInventors: Peter David Davis, Graeme Dougherty
-
Publication number: 20040058972Abstract: Vascular damaging agents composed of substituted 5(6)-substituted benzimidazole-2-carbamates are provided. These agents are useful in the preparation of medicaments for the treatment of diseases involving neovascularisation, particularly for the treatment of solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis.Type: ApplicationFiled: July 3, 2003Publication date: March 25, 2004Inventor: Peter David Davis
-
Patent number: 6645950Abstract: Vascular damaging agents composed of substituted 5(6)-substituted benzimidazole-2-carbamates are provided. These agents are useful in the preparation of medicaments for the treatment of diseases involving neovascularisation, particularly for the treatment of solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis. Embodiments include a 5(6)-substituted benzimidazole-2-carbamate of formula I wherein A represents a multi-substituted alkyl group or aromatic ring.Type: GrantFiled: October 22, 2001Date of Patent: November 11, 2003Assignee: Angiogene Pharmaceuticals Ltd.Inventor: Peter David Davis
-
Publication number: 20030181424Abstract: Compositions for the inhibition of the formation of new vaculature by angiogenesis are provided as in compounds which are salts comprising as an acidic component a compound of formula (1) wherein: R1, R2 and R3 are each independently alkyl, R4 is alkoxy, haloalkoxy, alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl, hydroxy or halo, R5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxy, phosphate or halo, and, as the basic component, a compound selected from the group consisting of (2) a compound of formula (2) wherein R6 is hydrogen or alkyl R7 is alkyl, alkylamino, dialkylamino, nitroamino, hydrazine, mercapto or alkylthio X is CH2, CH2CH2, CH2S, CH2CH2S Y is NH or S or a compound of formula (3) wherein R8 is alkyl or aminoalkyl R9 is hydrogen, alkyl or optionally substituted phenyl or, a compound of formula (4) wherein Z is 0, S, CH2, CHR13 or a bond R10, R11, R12 and R13 are each independently alkyl or hydrogen or, a compound of formula (5) wherein R14 is alkyl and the pharmaceuticType: ApplicationFiled: February 14, 2003Publication date: September 25, 2003Inventor: Peter David Davis
-
Publication number: 20030166617Abstract: The invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of the following therapies: i) ionising radiation; ii) a platinum anti-tumour agent; and iii) a taxane. The invention also relates to the use of ZD6126 and one of the above therapies in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal such as a human and to pharmaceutical compositions and kits each comprising ZD6126 and one of a platinum anti-tumour agent and a taxane.Type: ApplicationFiled: April 4, 2003Publication date: September 4, 2003Inventors: Peter David Davis, Graeme Dougherty
-
Publication number: 20030153755Abstract: Fused bicyclic amines of formula (1) are described wherein Ar is an aryl or heteroaryl group; Y is a —S(O2)— or —C(O)— group; R1 is a hydrogen or halogen atom or an alkyl, haloalkyl, alkoxy, haloalkoxy or cyano group; X is a nitrogen atom or a C(R1a) group where R1a is as defined for R1 and may be the same or different; W and Z are each a carbon atom and together with U form an optionally substituted five- or six-membered monocyclic aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the activity of Class I receptor tyrosine kinases and are of use in the prophylaxis and treatment of hyperproliferative disorders such as cancer, psoriasis, restenosis, atherosclerosis and fibrosis.Type: ApplicationFiled: February 4, 2003Publication date: August 14, 2003Inventors: David Festus Charles Moffat, Peter David Davis
-
Patent number: 6599908Abstract: Fused polycyclic 2-aminopyrimidines of formula (1): wherein Ar is an optionally substituted aromatic or heteroaromatic group; X is a carbon or nitrogen atom; Y is a carbon or nitrogen atom; Z is a linker group; A together with X and Y forms an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof are described. The compounds are potent and selective inhibitors of the protein tyrosine kinases p56lck and p59fyn and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56lck and/or p59fyn activity is believed to have a role.Type: GrantFiled: March 2, 2000Date of Patent: July 29, 2003Assignee: Celltech R & D LimitedInventors: Jeremy Martin Davis, Peter David Davis, David Festus Charles Moffat, Mark James Batchelor
-
Patent number: 6552029Abstract: Compounds of general formula (1) are described wherein: Ar is an optionally substituted aromatic group; R2 is a hydrogen or halogen atom or a group —X1—R2a where X1 is a direct bond or a linker atom or group, and R2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R3 is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.Type: GrantFiled: October 20, 1999Date of Patent: April 22, 2003Assignee: Celltech R&D LimitedInventors: Peter David Davis, David Festus Charles Moffat, Mark James Batchelor, Martin Clive Hutchings, David Mark Parry
-
Publication number: 20030055024Abstract: The invention concerns the use of a vascular damaging agent or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human. In particular the vascular damaging agent is ZD6126, or a pharmaceutically acceptable salt thereof. The invention also relates to methods of treatment using a vascular damaging agent in divided doses.Type: ApplicationFiled: September 26, 2002Publication date: March 20, 2003Inventor: Peter David Davis
-
Patent number: 6337335Abstract: Compounds of formula (1) are described: and the salts, solvates, hydrates and N-oxides thereof, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings given in claim 1. The compounds are selective inhibitors of protein kinases, especially src-family protein kinases and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.Type: GrantFiled: October 20, 1999Date of Patent: January 8, 2002Assignee: Celltech Therapeutics LimitedInventors: Martin Clive Hutchings, Peter David Davis, David Festus Charles Moffat
-
Patent number: 6235746Abstract: Compounds of general formula (1) are described: wherein R1 is a hydrogen or halogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group or a group selected from hydroxyl (—OH), substituted hydroxyl, thiol (—SH), substituted thiol, amino (—NH2), or substituted amino; R2 and R3, which may be the same or different, is each an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R4 is a hydrogen atom or a straight or branched chain alkyl group; R5 is a hydrogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R6 is a hydrogen or halogen atom or an amino (—NH2), substituted amino, nitro, carboxyl (—CO2H) or esterified carboxyl group or a group —X1—R6a where X1 is a direct bond or a linker atom or group and R6a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; X is a direct bond or a linker atom orType: GrantFiled: February 16, 1999Date of Patent: May 22, 2001Assignee: Celltech Therapeutics, LimitedInventors: Peter David Davis, David Festus Charles Moffat, Jeremy Martin Davis, Martin Clive Hutchings